AlphaQuest LLC Sells 11,489 Shares of Hologic, Inc. $HOLX

AlphaQuest LLC decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 90.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,256 shares of the medical equipment provider’s stock after selling 11,489 shares during the period. AlphaQuest LLC’s holdings in Hologic were worth $82,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in HOLX. Chung Wu Investment Group LLC bought a new stake in Hologic in the second quarter valued at $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 273 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of Hologic during the first quarter valued at about $34,000. Cromwell Holdings LLC raised its stake in Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 436 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 216 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.2%

NASDAQ:HOLX opened at $74.23 on Thursday. The company’s 50 day moving average price is $68.70 and its 200-day moving average price is $64.93. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $81.13. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The stock has a market cap of $16.51 billion, a price-to-earnings ratio of 30.80, a PEG ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.01 EPS. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is owned by insiders.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of research analyst reports. Mizuho downgraded Hologic from an “outperform” rating to a “neutral” rating and upped their target price for the stock from $70.00 to $78.00 in a report on Thursday, October 23rd. Argus lifted their price target on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Finally, Morgan Stanley upped their target price on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.23.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.